KLRSKalaris Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Kalaris Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KLRSEsta | $76M#9 | — | 1.3x#3 | 463.1x#6 | — | 37.2%#3 | -27970.9%#7 | -75.3%#8 | — | — | -34.8%#3 | — |
| ENGN | $127M#3 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#10 | — | -50.9%#6 | — | — | — | — |
| BDTX | $112M#4 | — | 1.2x#2 | 1.6x#3 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | -38.4%#4 | — |
| CRDF | $100M#7 | — | 3.8x#8 | 167.9x#5 | -13.2%#3 | -0.9%#5 | -8256.3%#5 | -0.2%#4 | — | — | — | — |
| ATTO | $1.0B#1 | — | — | — | — | — | — | — | — | — | — | — |
| ATRA | $100M#6 | — | — | 0.8x#1 | -6.3%#2 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#1 | — |
| CGTX | $101M#5 | — | 3.1x#7 | — | — | 30.9%#4 | — | -71.1%#7 | — | — | -27.6%#2 | — |
| ELOX | $75M#10 | 5.2x#2 | 1.6x#4 | — | -100.0%#4 | -90.7%#9 | — | -12.9%#5 | — | — | — | — |
| BSEM | $74M#11 | — | 2.7x#6 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PTHS | $77M#8 | — | — | 4.6x#4 | — | -444.6%#12 | -193.1%#4 | — | — | — | — | — |
| SCTX | $539M#2 | — | — | — | — | — | — | — | — | — | — | — |
| CSBR | $68M#13 | — | 17.5x#10 | 1.1x#2 | 4.4%#1 | -125.0%#11 | -1.9%#3 | -0.0%#3 | — | — | — | — |
| LONA | $68M#12 | — | 2.0x#5 | — | — | -9.3%#6 | — | -315.5%#10 | — | — | — | — |
| EXOZ | $60M#14 | — | 16.5x#9 | 861.0x#7 | — | -56.3%#8 | -13867.0%#6 | -250.6%#9 | — | — | — | — |
| INKT | $59M#15 | — | — | — | — | -15.9%#7 | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice